MX2016001837A - Receptores de celulas t. - Google Patents

Receptores de celulas t.

Info

Publication number
MX2016001837A
MX2016001837A MX2016001837A MX2016001837A MX2016001837A MX 2016001837 A MX2016001837 A MX 2016001837A MX 2016001837 A MX2016001837 A MX 2016001837A MX 2016001837 A MX2016001837 A MX 2016001837A MX 2016001837 A MX2016001837 A MX 2016001837A
Authority
MX
Mexico
Prior art keywords
tcrs
lmp2a
tcr
complex
ebv
Prior art date
Application number
MX2016001837A
Other languages
English (en)
Inventor
Qin Su
Peter Molloy
Nathaniel Liddy
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of MX2016001837A publication Critical patent/MX2016001837A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a receptores de células T (TCRs) que se unen al péptido CLGGLLTMV restringido en HLA-A2 derivado de la proteína LMP2A del Virus de Epstein Barr (EBV). Los TCRs de la invención comprenden un dominio variable de la cadena alfa de TCR y/o un dominio variable beta de TCR. Ciertos TCRs preferidos se unen también a las variantes de péptido natural SLGGLLTMV y CLGGLITMV presentadas como un complejo péptido-HLA-A2. Los TCRs de la invención demuestran excelentes perfiles de especificidad para aquellos epítopos de LMP2A y tienen afinidades de unión para el complejo que se traducen en una capacidad mejorada para reconocer el complejo en comparación con un TCR de referencia soluble que tiene la secuencia extracelular de la cadena alfa de TCR de LMP2A de EBV nativa mostrada en la figura 3 (SEQ ID NO: 4) y la secuencia extracelular de la cadena beta de TCR de LMP2A de EBV nativa mostrada en la figura 4 (SEQ ID NO: 5).
MX2016001837A 2013-08-12 2014-08-12 Receptores de celulas t. MX2016001837A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1314404.3A GB201314404D0 (en) 2013-08-12 2013-08-12 T Cell Receptors
PCT/GB2014/052464 WO2015022520A1 (en) 2013-08-12 2014-08-12 T cell receptors

Publications (1)

Publication Number Publication Date
MX2016001837A true MX2016001837A (es) 2016-05-24

Family

ID=49262046

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001837A MX2016001837A (es) 2013-08-12 2014-08-12 Receptores de celulas t.

Country Status (16)

Country Link
US (1) US20160199479A1 (es)
EP (1) EP3033353A1 (es)
JP (1) JP2016528244A (es)
KR (1) KR20160058767A (es)
CN (1) CN106414482A (es)
AU (1) AU2014307725A1 (es)
BR (1) BR112016002687A2 (es)
CA (1) CA2920444A1 (es)
EA (1) EA201690180A1 (es)
GB (1) GB201314404D0 (es)
HK (1) HK1221724A1 (es)
MX (1) MX2016001837A (es)
PH (1) PH12016500272A1 (es)
SG (1) SG11201600849UA (es)
WO (1) WO2015022520A1 (es)
ZA (1) ZA201600959B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279404A (zh) * 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 一种可溶且稳定的异质二聚tcr
AU2016323017B2 (en) * 2015-09-15 2020-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-Cw8 restricted mutated KRAS
WO2017079747A1 (en) 2015-11-06 2017-05-11 Regents Of The University Of Minnesota Activation of resident memory t cells for cancer immunotherapy
GB201520191D0 (en) * 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
US10611816B2 (en) * 2016-08-02 2020-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-KRAS-G12D T cell receptors
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
DE102017114737A1 (de) * 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
US20210093713A1 (en) * 2017-08-03 2021-04-01 Regents Of The University Of Minnesota Activation of resident memory t cells for the treatment of cancer
CN110818802B (zh) * 2018-08-08 2022-02-08 华夏英泰（北京）生物技术有限公司 一种嵌合t细胞受体star及其应用
CN109306005B (zh) * 2018-09-30 2019-11-15 清华大学 一种eb病毒特异性t细胞抗原受体及其应用
CN113423724B (zh) * 2018-12-27 2023-11-24 深圳华大生命科学研究院 Ebv表位高亲和力t细胞受体
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
EP3786178A1 (en) 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
WO2021211455A1 (en) * 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
CN111440246B (zh) * 2020-04-16 2022-03-18 成都仕康美生物科技有限公司 靶向HLA-B的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途
CA3217738A1 (en) 2021-05-05 2022-05-04 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023242343A1 (en) * 2022-06-15 2023-12-21 Immunoscape Pte. Ltd. Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223399D0 (en) * 2002-10-09 2002-11-13 Avidex Ltd Receptors
GB0917090D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
PL2618835T3 (pl) * 2010-09-20 2017-12-29 Biontech Cell & Gene Therapies Gmbh Swoiste względem antygenu receptory komórek T i epitopy dla komórek T

Also Published As

Publication number Publication date
SG11201600849UA (en) 2016-03-30
GB201314404D0 (en) 2013-09-25
KR20160058767A (ko) 2016-05-25
EA201690180A1 (ru) 2016-07-29
JP2016528244A (ja) 2016-09-15
CA2920444A1 (en) 2015-02-19
EP3033353A1 (en) 2016-06-22
AU2014307725A1 (en) 2016-03-03
CN106414482A (zh) 2017-02-15
BR112016002687A2 (pt) 2017-09-12
WO2015022520A1 (en) 2015-02-19
US20160199479A1 (en) 2016-07-14
PH12016500272A1 (en) 2016-05-02
HK1221724A1 (zh) 2017-06-09
ZA201600959B (en) 2017-11-29

Similar Documents

Publication Publication Date Title
PH12016500272A1 (en) T cell receptors
NZ715038A (en) T cell receptors
PH12018502158A1 (en) T cell receptors
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
PH12018501250A1 (en) Chimeric factor viii polypeptides and uses thereof
MX2019015532A (es) Receptores de celulas t.
MX2019009641A (es) Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida.
WO2018083087A3 (en) Binding proteins
UA111820C2 (uk) Модифікований зв'язуючий протеїн, що інгібує взаємодію vegf-а-рецептора
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EA201691078A1 (ru) Терапевтические пептиды
MX366223B (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
MX361076B (es) Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
IN2014DN10288A (es)
MX2013002173A (es) Formas farmaceuticas dirigidas de epitopos multiples para la induccion de una respuesta inmunologica frente a antigenos.
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
MX354660B (es) Remocion de las celulas de cancer por celulas t citotoxicas, especificas de virus, en circulacion, usando proteinas multifuncionales que comprenden complejo de histocompatilibidad principal (mhc) clase i, dirigidas a celulas de cancer.
MX2022008337A (es) Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada.
NZ594198A (en) Neil3 peptides and vaccines including the same
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
MY177371A (en) Peptides
EP2528937A4 (en) MODIFIED MELK PEPTIDES AND ASSOCIATED VACCINES
NZ702285A (en) Staphylococcal coagulase antigens and methods of their use
MA40526A (fr) Protéines de fixation antigénique fixant le cxcr3